Trial reportCancer2008
Phase 2 trial of pemetrexed disodium and gemcitabine in advanced urothelial cancer (E4802): a trial of the Eastern Cooperative Oncology Group.
Trial report in Cancer, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00053209 (Phase II Trial Of Pemetrexed Disodium And Gemcitabine In Advanced Urothelial Cancer), which is not on this map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Phase II Trial Of Pemetrexed Disodium And Gemcitabine In Advanced Urothelial Cancer
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it, 29 citations in OpenAlex.
- SIU-ICUD recommendations on bladder cancer: systemic therapy for metastatic bladder cancer.World journal of urology · 2019Guideline
- Phase II study of pemetrexed in combination with cisplatin in patients with advanced urothelial cancer: the PECULIAR study (KCSG 10-17).British journal of cancer · 2015Trial
- Unusually prolonged pemetrexed cytotoxicity in a patient with a lung adenocarcinoma: a case report.Journal of medical case reports · 2017Article
- Article
- Article
- Systemic therapy for bladder cancer - a medical oncologist's perspective.Journal of solid tumors · 2014Article
- Personalized therapy for urothelial cancer: review of the clinical evidence.Clinical investigation · 2011Article
- Update on chemotherapy in the treatment of urothelial carcinoma.TheScientificWorldJournal · 2011Review
- Update in Urothelial Carcinoma: Novel Agents and Targeted Therapy.American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting · 2011Article
- Current therapeutic strategies for invasive and metastatic bladder cancer.OncoTargets and therapy · 2011Article
- First- and second-line therapy for metastatic urothelial carcinoma of the bladder.Current oncology (Toronto, Ont.) · 2011Article
- Choosing chemotherapy in patients with advanced urothelial cell cancer who are unfit to receive cisplatin-based chemotherapy.Therapeutic advances in medical oncology · 2010Article
- [Systemic chemotherapy for bladder cancer: news in 2009].Der Urologe. Ausg. A · 2009Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 1 country.
Funding
Abstract
backgroundThere is a need to identify active new regimens in patients with advanced urothelial cancer. Pemetrexed and gemcitabine are active agents in advanced urothelial cancer. A phase 2 trial of the combination of these 2 agents was performed in patients with advanced urothelial cancer who were previously untreated for metastatic disease.
methodsForty-six patients with advanced urothelial carcinoma received pemetrexed disodium 500 mg/m2 and gemcitabine 1000 mg/m2 intravenously on Day 1, with gemcitabine repeated on Day 8. Cycles were repeated every 3 weeks for a maximum of 6 cycles.
resultsTwo patients attained a complete response, and 12 patients attained a partial response for an overall response rate of 31.8% (90% confidence interval, 20.4%-45.2%). The median time to disease progression was 5.8 months, and the median overall survival was 13.4 months. Thirty-three patients (75%) experienced grade>or=3 neutropenia, and 5 patients (11%) had febrile neutropenia. There were 2 therapy-related deaths.
conclusionsThe combination of pemetrexed and gemcitabine had moderate antitumor activity in previously untreated patients with advanced urothelial cancer at the expense of significant myelosuppression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.